Stereoselective synthesis and anti-proliferative effects on prostate cancer evaluation of 5-substituted-3,4-diphenylfuran-2-ones

European Journal of Medicinal Chemistry

Volumn 65, Issue , 2013, Pages 323-336

  Liu, Gai Zhi ^a   Xu, Hai Wei ^b   Wang, Peng ^b   Lin, Zong Tao ^c   Duan, Ying Chao ^b   Zheng, Jia Xin ^b   Liu, Hong Min ^b  

^a HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

5 Substituted 3,4 diphenylfuran 2 one; Anti proliferative; Cell cycle arrest; Prostate cancer; Rofecoxib

Indexed keywords

(5Z) 4 [4 (METHYLSULFONYL)PHENYL] 5 [(NAPHTHALEN 1 YL)METHYLENE] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (2 METHOXYBENZYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (3 NITROBENZYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (3,4,5 TRIMETHOXYBENZYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (3,7 DIMETHYLOCTA 2,6 DIENYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (4 CHLOROBENZYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (4 FLUOROBENZYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (4 HYDROXY 3 METHOXYBENZYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (4 HYDROXYBENZYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 (4 METHOXYBENZYLIDENE) 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 BENZYLIDENE 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 [(BENZO[D][1,3]DIOXOL 5 YL)METHYLENE] 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 [(FURAN 2 YL)METHYLENE] 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; (5Z) 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; 3 (2 CHLOROPHENYL) 5 (FURAN 2 YLMETHYLENE) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 3 (2 CHLOROPHENYL) 5 [(1,3 DIHYDROISOBENZOFURAN 5 YL)METHYLENE] 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 4 [4 (METHYLSULFONYL)PHENYL) 3 PHENYL 5 (PROPAN 2 YLIDENE)FURAN 2(5H) ONE; 5 (2 METHOXYBENZYLIDENE) 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 5 (3 NITROBENZYLIDENE) 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 5 (3,4,5 TRIMETHOXYBENZYLIDENE) 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 5 (4 BROMOBENZYLIDENE) 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 5 (4 CHLOROBENZYLIDENE) 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 5 (4 FLUOROBENZYLIDENE) 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 5 (4 HYDROXY 3 METHOXYBENZYLIDENE) 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 5 (4 HYDROXYBENZYLIDENE) 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; 5 BENZYLIDENE 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL) PHENYL]FURAN 2(5H) ONE; 5 METHOXY 5 METHYL 4 [4 (METHYLSULFONYL)PHENYL] 3 PHENYLFURAN 2(5H) ONE; 5 [4 (DIMETHYLAMINO)BENZYLIDENE] 3 (2 CHLOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL]FURAN 2(5H) ONE; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 84878408061     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.04.062     Document Type: Article

References (35)

1. H. Fujita, K. Koshida, E.T. Keller, Y. Takahashi, T. Yoshimito, M. Namiki, A. Mizokami, Cyclooxygenase-2 promotes prostate cancer progression, The Prostate 53 (2002) 232-240. (Pubitemid 35266184)
2. J.V. Adelsberg, P. Gann, A.T. Ko, J.-E. Damber, C. Logothetis, M. Marberger, B.J. Schmitz-Drager, A. Tubaro, C.J. Harms, C. Roehrborn, The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups, Curr. Med. Res. Opin. 23 (2007) 2063-2070. (Pubitemid 350246594)
3. S.H. Landis, T. Murry, S. Bolden, P.A. Wingo, Cancer statistics, CA Cancer J. 48 (1998) 6-29.
4. R.R. Tjandrawinata, R. Dahiya, M. Hughes-Fulford, Induction of cyclooxygenase-2 mRNA by prostaglandin E2, in human prostatic carcinoma cells, Br. J. Cancer 75 (1997) 1111-1118. (Pubitemid 27140020)
5. F.M. Hughes, Y. Chen, R.R. Tjandrawinata, Fatty acid regulates gene expression and growth of human prostate cancerPC-3 cells, Carcinogenesis 22 (2001) 701-707. (Pubitemid 32447916)
6. G.D. Lorenzo, S.D. Placido, R. Autorino, M.D. Laurentiis, C. Mignogna, M. D'Armiento, G. Tortora, G.D. Rosa, M. D'Armiento, M.D. Sio, A.R. Bianco, F.P. D'Armiento, Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease, Prostate Cancer Prostatic Dis. 8 (2005) 54-59.
7. X.H. Liu, A. Kirschenbaum, S. Yao, R. Lee, J.F. Holland, A.C. Levine, Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo, J. Urol. 164 (2000) 820-825. (Pubitemid 30637640)
8. F.A. Attiga, P.M. Fernandez, A.T. Weeraratna, M.J. Manyak, S.R. Patierno, Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases, Cancer Res. 60 (2000) 4629-4637. (Pubitemid 32103650)
9. S. Gupta, M. Srivastava, N. Ahmad, D.G. Bostwick, H. Mukhtar, Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma, Prostate 42 (2000) 73-78. (Pubitemid 30004877)
10. R.O. Roberts, D.J. Jacobson, C.J. Girman, T. Rhodes, M.M. Lieber, S.J. Jacobsen, A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer, Mayo Clin. Proc. 77 (2002) 219-225. (Pubitemid 34177596)
11. M.J. Thun, S.J. Henley, C. Patrono, Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues, J. Natl. Cancer Inst. 94 (2002) 252-266. (Pubitemid 34196319)
12. S.K. Kulp, Y.T. Yang, C.C. Hung, K.F. Chen, J.P. Lai, P.H. Tseng, J.W. Fowble, P.J. Ward, C.S. Chen, 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells, Cancer Res. 64 (2004) 1444-1451. (Pubitemid 38235615)
13. P.N.P. Rao, Md. J. Uddin, E.E. Knaus, Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylfuran-2-ones as selective cyclooxygenase-2 inhibitors, J. Med. Chem. 47 (2004) 3972-3990. (Pubitemid 38970959)
14. E. Giovannucci, E.B. Rimm, M.J. Stampfer, G.A. Colditz, A. Ascherio, W.C. Willett, Aspirin use and the risk for colorectal cancer and adenoma in male health professionals, Ann. Intern. Med. 121 (1994) 241-246.
15. M.J. Thun, M.M. Namboodiri, E.E. Calle, W.D. Flanders, C.W. Heath Jr., Aspirin use and risk of fatal cancer, Cancer Res. 53 (1993) 1322-1327. (Pubitemid 23097110)
16. K. Subbaramaiah, A.J. Dannenberg, Cyclooxygenase 2: a molecular target for cancer prevention and treatment, Trends Pharmacol. Sci. 24 (2003) 96-102. (Pubitemid 36135884)
17. K.P. Teismann, D.K. Tieu, D.C. Choi, W.A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, S. Przedborski, Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5473-5478. (Pubitemid 36542729)
18. H. Fujita, K. Koshida, E.T. Keller, Y. Takahashi, T. Yoshimito, M. Namiki, A. Mizokami, Cyclooxygenase-2 promotes prostate cancer progression, Prostate 53 (2002) 232-240. (Pubitemid 35266184)
19. Z. Xiang, L. Ho, S. Yemul, Z. Zhao, W. Qing, P. Pompl, K. Kelley, A. Dang, W. Qing, D. Teplow, G.M. Pasinetti, Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology, Gene Expr. 10 (2002) 271-278. (Pubitemid 35315389)
20. G.Z. Liu, D.N. Han, P. Wang, H.M. Liu, The synthesis research progress of rofecoxib and its derivatives, Chin. J. Org. Chem (2013), http://dx.doi.org/10. 6023/cjoc201212050.
21. (a) C.C. Chan, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, A.W.F. Hutchinson, M.J. Forrest, J.Y. Gauthier, R. Gordon, M. Gresser, J. Guay, S. Kargman, B. Kennedy, Y. Leblanc, S. Leger, J. Mancini, G.P. O'neill, M. Ouellet, D. Patrick, M.D. Percival, H. Perrier, P. Prasit, I. Rodger, P. Tagari, M. Therien, P. Vickers, D. Visco, Z. Wang, J. Webb, E. Wong, L.-J. Xu, R.N. Young, R. Zamboni, D. Riendeau, Rofecoxib [Vioxx, MK-0966; 4-(49-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther. 290 (1999) 551-560;
22. (b) P. Prasit, Z.Wang, C. Brideau, C.-C. Chan, S. Charleson, W. Cromlish, D. Ethier, J.F. Evans, A.W. Ford-Hutchinson, J.Y. Gauthier, R. Gordon, J. Guay, M. Gresser, S. Kargman, B. Kennedy, Y. Leblanc, S. Léger, J. Mancini, G.P. O'Neill, M. Ouellet, M.D. Percival, H. Perrier, D. Riendeau, I. Rodger, P. Tagari, M. Thérien, P. Vickers, E. Wong, L.-J. Xu, R.N. Young, R. Zamboni, The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′- methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor, Bioorg. Med. Chem. Lett. 9 (1999) 1773-1778.
23. M. Thérien, J.Y. Gauthier, Y. Leblanc, S. Léger, H. Perrier, P. Prasit, Z.Y. Wang, Synthesis of rofecoxib, (MK 0966, Vioxx® 4-(4¢-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone), a selective and orally active inhibitor of cyclooxygenase-2, Synthesis 12 (2001) 1778-1779. (Pubitemid 32929647)
24. L.R. Reddy, E.J. Corey, Facile air oxidation of the conjugate base of rofecoxib (VioxxTM), a possible contributor to chronic human toxicity, Tetrahedron Lett. 46 (2005) 927-929. (Pubitemid 40137930)
25. P.N.P. Rao, M. Amini, H.Y. Li, A.G. Habeeb, E.E. Knaus, Design, synthesis, and biological evaluation of 6-substituted-3-(4- methanesulfonylphenyl)-4-phenylfuran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors, J. Med. Chem. 46 (2003) 4872-4882. (Pubitemid 37352027)
26. J.J. Talley, Selective inhibitors of cyclooxygenase-2 (COX-2), Progr. Med. Chem. 36 (1999) 201-233.
27. P.N.P. Rao, M. Amini, H. Li, A.G. Habeeb, E.E. Knaus, 6-Alkyl, alkoxy, or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 13 (2003) 2205-2209. (Pubitemid 36694305)
28. G.Z. Liu, H.W. Xu, G.W. Chen, P. Wang, Y.N. Wang, H.M. Liu, D.Q. Yu, Stereoselective synthesis of desloratadine derivatives as antagonist of histamine, Bioorg. Med. Chem. 18 (2010) 1626-1632.
29. H.W. Xu, J.F. Wang, G.Z. Liu, G.F. Hong, H.M. Liu, Facile synthesis of γ-AIBs, Org. Biomol. Chem. 5 (2007) 1247-1250.
30. H.W. Xu, G.F. Dai, G.Z. Liu, J.F. Wang, H.M. Liu, Synthesis of andrographolide derivatives: a new family of α-glucosidase inhibitors, Bioorg. Med. Chem. 15 (2007) 4247-4251.
31. H.W. Xu, G.Z. Liu, G.F. Dai, C.L. Wu, H.M. Liu, Modification of 15-akylidene andrographolide derivatives as alpha-glucosidase inhibitor, Drug Discovery Ther. 1 (2007) 73-77.
32. G.F. Dai, H.W. Xu, J.F. Wang, F.W. Liu, H.M. Liu, Studies on the novel α-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues, Bioorg. Med. Chem. Lett. 16 (2006) 2710-2713.
33. A Snapshot of Prostate Cancer, National Cancer Institute, Sept. 2009.
34. M.D.H. Lepor, Challenging the current treatment paradigm of androgen-independent prostate cancer, Rev. Urol. 9 (2007) 51-52.
35. A.L. Hsu, T.T. Ching, D.S. Wang, X.Q. Song, V.M. Rangnekar, C.S. Chen, The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2, J. Biol. Chem. 275 (2000) 11397-11400.